These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17596715)

  • 1. Caenorhabditis elegans as a model system for Parkinson's disease.
    Schmidt E; Seifert M; Baumeister R
    Neurodegener Dis; 2007; 4(2-3):199-217. PubMed ID: 17596715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease.
    Harrington AJ; Hamamichi S; Caldwell GA; Caldwell KA
    Dev Dyn; 2010 May; 239(5):1282-95. PubMed ID: 20108318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.
    Locke CJ; Fox SA; Caldwell GA; Caldwell KA
    Neurosci Lett; 2008 Jul; 439(2):129-33. PubMed ID: 18514411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caenohabditis elegans in Parkinson's disease drug discovery: addressing an unmet medical need.
    Nass R; Merchant KM; Ryan T
    Mol Interv; 2008 Dec; 8(6):284-93. PubMed ID: 19144901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study of molecular mechanism of anti-Parkinson's disease traditional Chinese medicine using model of Caenorhabditis elegans].
    Wang X; Wang X; Gao H; Wang D
    Zhongguo Zhong Yao Za Zhi; 2010 Mar; 35(5):661-3. PubMed ID: 20506834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sir-2.1 modulates 'calorie-restriction-mediated' prevention of neurodegeneration in Caenorhabditis elegans: implications for Parkinson's disease.
    Jadiya P; Chatterjee M; Sammi SR; Kaur S; Palit G; Nazir A
    Biochem Biophys Res Commun; 2011 Sep; 413(2):306-10. PubMed ID: 21889494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caenorhabditis elegans: a useful tool to decipher neurodegenerative pathways.
    Johnson JR; Jenn RC; Barclay JW; Burgoyne RD; Morgan A
    Biochem Soc Trans; 2010 Apr; 38(2):559-63. PubMed ID: 20298221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling dopamine neuron degeneration in Caenorhabditis elegans.
    Tucci ML; Harrington AJ; Caldwell GA; Caldwell KA
    Methods Mol Biol; 2011; 793():129-48. PubMed ID: 21913098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease.
    Link CD
    Exp Gerontol; 2006 Oct; 41(10):1007-13. PubMed ID: 16930903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease.
    Jadiya P; Khan A; Sammi SR; Kaur S; Mir SS; Nazir A
    Biochem Biophys Res Commun; 2011 Oct; 413(4):605-10. PubMed ID: 21925152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling neurodegenerative diseases in Caenorhabditis elegans.
    Li J; Le W
    Exp Neurol; 2013 Dec; 250():94-103. PubMed ID: 24095843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C. elegans as a genetic model system to identify Parkinson's disease-associated therapeutic targets.
    Vistbakka J; VanDuyn N; Wong G; Nass R
    CNS Neurol Disord Drug Targets; 2012 Dec; 11(8):957-64. PubMed ID: 23244419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD.
    Mandel SA; Fishman T; Youdim MB
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S242-7. PubMed ID: 18267243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease.
    McFarlane D
    Ageing Res Rev; 2007 May; 6(1):54-63. PubMed ID: 17374512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease: insights from non-traditional model organisms.
    Pienaar IS; Götz J; Feany MB
    Prog Neurobiol; 2010 Dec; 92(4):558-71. PubMed ID: 20851733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin-proteasome system dysfunction in Parkinson's disease: current evidence and controversies.
    Lim KL
    Expert Rev Proteomics; 2007 Dec; 4(6):769-81. PubMed ID: 18067415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unraveling the role of defective genes in Parkinson's disease.
    Dawson TM
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S248-9. PubMed ID: 18267244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addiction research in a simple animal model: the nematode Caenorhabditis elegans.
    Schafer WR
    Neuropharmacology; 2004; 47 Suppl 1():123-31. PubMed ID: 15464131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling human diseases in Caenorhabditis elegans.
    Markaki M; Tavernarakis N
    Biotechnol J; 2010 Dec; 5(12):1261-76. PubMed ID: 21154667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciphering the neural and molecular mechanisms of C. elegans behavior.
    Schafer WR
    Curr Biol; 2005 Sep; 15(17):R723-9. PubMed ID: 16139205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.